(Natural News) Pancreatic ductal adenocarcinoma, or PDA, is the most common and by far the most lethal form of pancreatic cancer. Pancreapedia reports that it is extremely aggressive, and for most patients their only hope of survival hinges on the total surgical removal of the tumor. Unfortunately, such tumors cannot be removed in upwards of…

Source: NaturalNews.comCategory: Consumer Health News Source Type: news

Related Links:

ConclusionCombination of systemic chemotherapy and oligometastasectomy with adjunctive local IRE therapy is a feasible treatment strategy in highly select patients with oligometastatic PDAC that demonstrate favorable tumor biology with objective response to systemic therapy.

Publication date: September 2018Source: Clinica Chimica Acta, Volume 484Author(s): Song Mao, Xiaopeng Wang, Liangxia Wu, Dou Zang, Wenjing ShiAbstractBackgroundWe assessed the association between tissue klotho protein expression and the risk and progression of malignancies.MethodsWe searched the electronic databases for the studies regarding the relationship between tissue klotho protein expression and risk/progression of malignancies through January 2018. We calculated the pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) to evaluate the impact of tissue klotho protein expression on malignancies. A…

In conclusion, our results suggest that miR-1297 inhibits the growth and metastasis of pancreatic adenocarcinoma by downregulating MTDH expression, and the miR-1297/MTDH pathway is a potential target for treating pancreatic adenocarcinoma.

Publication date: Available online 28 June 2018Source: Advances in Biological RegulationAuthor(s): Stephen L. Abrams, Kvin Lertpiriyapong, Li V. Yang, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Marco Falasca, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Massimo Libra, Saverio Candido, Giuseppe Montalto, Melchiorre Cervello, Linda S. Steelman, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10%. Mutations at the TP53 gene are read…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Saverio Candido, Stephen L. Abrams, Linda Steelman, Kvin Lertpiriyapong, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Matilde Y. Follo, Ramiro M. Murata, Pedro L. Rosalen, Paolo Lombardi, Giuseppe Montalto, Melchiorre Cervello, Agnieszka Gizak, Dariusz Rakus, Pann-Gill Suh, Massimo Libra, James A. McCubreyAbstractPancreatic ductal adenocarcinoma (PDAC) is an aggressive, highly metastatic malignancy and accounts for 85% of pancreatic cancers. PDAC patients have poor prognosis with a five-year survival of only 5–10% after diagn…

Publication date: May 2018Source: Advances in Biological Regulation, Volume 68Author(s): Aleksandra Adamska, Omar Elaskalani, Aikaterini Emmanouilidi, Minkyoung Kim, Norbaini Binti Abdol Razak, Pat Metharom, Marco FalascaAbstractPancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant cancers, and current therapies targeting cancer-associated molecular pathways have not given satisfactory results, owing in part to rapid upregulation of alternative compensatory pathways. Most of the available treatments are palliative, focussing on improving the quality of life. At present, available options are surgery, em…

ConclusionSecond-opinion review by subspecialized oncologic radiologists can impact patient care, specifically in terms of management decision.

ConclusionsMajor cell-cycle regulator also have predictive significance, but further studies are required to evaluate this.

Publication date: June 2018Source: Pathology – Research and Practice, Volume 214, Issue 6Author(s): Deborah Saraggi, Francesca Galuppini, Giuseppe N. Fanelli, Andrea Remo, Emanuele D.L. Urso, Ricardo Q. Bao, Deborah Bacchin, Vincenza Guzzardo, Claudio Luchini, Chiara Braconi, Fabio Farinati, Massimo Rugge, Matteo FassanAbstractPoor information is available on the molecular landscape characterizing the carcinogenetic process leading to ampullary carcinoma. MiR-21 is one of the most frequently up-regulated miRNAs in pancreatic adenocarcinoma, a tumor sharing similar molecular features with ampullary adenocarcinomas (AVCs), a…

ConclusionOur results indicate a high acceptance of the S3-guidline recommendation for adCx in resected PDAC in a routine setting, which, however, is completed in only 50 % of all patients. Fully completed adCx had the most powerful effect on improving overall survival.





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image